This is definitely a list few, if any, companies want to be on. Source: BioSpace

The cash will support expansion in translational informatics, clinical trials, and broadened use of biomedical data. Source: BioSpace

A look at two biopharma companies that fall into this category that investors should check out. Source: BioSpace

Centrexion closed on a Series D financing worth $67M to develop its knee osteoarthritis drug in Phase III. Source: BioSpace

Three biotech companies want to start out the new year with a new start. Source: BioSpace

At closing of the agreement, $75 million in aggregate principal amount of the Senior Secured Notes were issued. Source: BioSpace

From around 2014 through 2016, Valeant seemingly had a crisis story per week, ranging from insider trading to channel stuffing Source: BioSpace

Menlo Therapeutics filed on Thursday with the SEC to raise up to $98M in an IPO. Source: BioSpace

ANI Phamaceuticals funded the acquisitions through a combination of cash and debt. Source: BioSpace

A look at a few biotechs which should outperform the market in 2018: Source: BioSpace